NeoGenomics Balance Sheet Health
Financial Health criteria checks 3/6
NeoGenomics has a total shareholder equity of $923.4M and total debt of $538.9M, which brings its debt-to-equity ratio to 58.4%. Its total assets and total liabilities are $1.6B and $716.9M respectively.
Key information
58.4%
Debt to equity ratio
US$538.92m
Debt
| Interest coverage ratio | n/a |
| Cash | US$384.83m |
| Equity | US$923.41m |
| Total liabilities | US$716.93m |
| Total assets | US$1.64b |
Recent financial health updates
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Aug 23
NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt
Apr 18We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt
Jan 10Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt
Aug 10Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?
Apr 22Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?
Jan 07Recent updates
Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues
Mar 30Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking
Dec 26Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Aug 23Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)
Jul 16NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt
Apr 18We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt
Jan 10NeoGenomics: Market Punishment Continues, But Looks Justified
Sep 30NeoGenomics grants CEO restricted shares, stock options
Aug 17Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt
Aug 10NeoGenomics rises ~14% on strong Q2 result
Aug 09NeoGenomics gets new CEO
Jul 21NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential
Jun 28Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?
Apr 22Neogenomics: Poor Performance, CEO Departure Create Downward Share Price Spiral
Apr 08Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching
Feb 11Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?
Jan 07NeoGenomics: Gambling On Growth
Dec 16NeoGenomics: Profitability Headwinds Compress Valuation, Shares
Sep 28Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?
Sep 24NeoGenomics: Strong Growth Potential For A Leader In Cancer Diagnostic Testing
Jul 02NeoGenomics completes Inivata acquisition
Jun 18Financial Position Analysis
Short Term Liabilities: NEO's short term assets ($573.9M) exceed its short term liabilities ($76.7M).
Long Term Liabilities: NEO's short term assets ($573.9M) do not cover its long term liabilities ($640.2M).
Debt to Equity History and Analysis
Debt Level: NEO's net debt to equity ratio (16.7%) is considered satisfactory.
Reducing Debt: NEO's debt to equity ratio has increased from 30.9% to 58.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NEO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NEO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.